| Literature DB >> 27210749 |
Hezhe Lu1, Shujing Liu2, Gao Zhang3, Lawrence N Kwong4, Yueyao Zhu1, John P Miller4, Yi Hu5, Wenqun Zhong1, Jingwen Zeng1, Lawrence Wu3, Clemens Krepler3, Katrin Sproesser3, Min Xiao3, Wei Xu6, Giorgos C Karakousis7, Lynn M Schuchter6, Jeffery Field8, Paul J Zhang2, Meenhard Herlyn3, Xiaowei Xu9, Wei Guo10.
Abstract
Melanoma patients with oncogenic BRAF(V600E) mutation have poor prognoses. While the role of BRAF(V600E) in tumorigenesis is well established, its involvement in metastasis that is clinically observed in melanoma patients remains a topic of debate. Here, we show that BRAF(V600E) melanoma cells have extensive invasion activity as assayed by the generation of F-actin and cortactin foci that mediate membrane protrusion, and degradation of the extracellular matrix (ECM). Inhibition of BRAF(V600E) blocks melanoma cell invasion. In a BRAF(V600E)-driven murine melanoma model or in patients' tumor biopsies, cortactin foci decrease upon inhibitor treatment. In addition, genome-wide expression analysis shows that a number of invadopodia-related genes are downregulated after BRAF(V600E) inhibition. Mechanistically, BRAF(V600E) induces phosphorylation of cortactin and the exocyst subunit Exo70 through ERK, which regulates actin dynamics and matrix metalloprotease secretion, respectively. Our results provide support for the role of BRAF(V600E) in metastasis and suggest that inhibiting invasion is a potential therapeutic strategy against melanoma.Entities:
Keywords: invadopodia; oncogenic BRAF; tumor invasion
Mesh:
Substances:
Year: 2016 PMID: 27210749 PMCID: PMC4889462 DOI: 10.1016/j.celrep.2016.04.073
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423